Hyalgan (Sodium Hyaluronate)

Hyalgan is a prescription intra‑articular injection that contains sodium hyaluronate as its active ingredient. The product is supplied in a sterile solution for joint administration, with the specific strength not disclosed in the labeling. Classified as a viscosupplement, Hyalgan is marketed in the European Union for use in patients with osteoarthritis of the knee, where it aims to improve joint function and reduce discomfort over time.

Hyalgan is indicated for the symptomatic management of osteoarthritis of the knee, particularly in patients whose pain and functional limitation persist despite standard non‑pharmacologic measures and oral analgesics.

- Decreases knee joint pain during weight‑bearing activities and at rest. - Enhances range of motion, allowing smoother flexion and extension. - Replenishes hyaluronic acid in the joint, improving lubrication and shock absorption. - May postpone or reduce the likelihood of total knee arthroplasty. - Can be combined with physiotherapy, exercise programs, and oral NSAIDs for comprehensive care.

Adverse reactions to intra‑articular Hyalgan are generally localized to the injection site, though systemic events have been reported in rare cases.

Common: - Transient pain or swelling at the injection site, usually resolving within a few days. - Mild warmth or flushing in the treated knee that subsides quickly. - Temporary stiffness or reduced range of motion lasting several hours to a day. - Minor bruising or skin discoloration around the injection area, which fades over time.

Serious: - Acute joint infection (septic arthritis) presenting with severe pain, fever, and rapid swelling. - Allergic reaction such as rash, itching, hives, or angio‑edema requiring medical evaluation. - Persistent joint effusion or intense inflammation that does not improve with standard care. - Rare cases of tendon rupture or ligament injury associated with the injection procedure.

When considering Hyalgan, clinicians should evaluate patient history and joint condition to minimize risks and ensure appropriate use.

- Confirm diagnosis of knee osteoarthritis and rule out inflammatory arthritis before injection. - Assess for active infection, skin lesions, or joint effusion at the treatment site. - Use aseptic technique and proper imaging guidance to avoid intra‑articular misplacement. - Evaluate renal or hepatic impairment, although systemic absorption is minimal. - Discuss potential need for repeat injections and cumulative exposure with the patient. - Monitor for adverse reactions after each administration and document findings.

Hyalgan may interact with other agents administered systemically or locally; awareness of potential interactions helps prevent complications.

Avoid: - Concurrent intra‑articular corticosteroid injection within 2 weeks, which may diminish Hyalgan’s efficacy. - Use of intra‑articular antibiotics or other viscosupplements at the same visit, increasing infection risk.

Use with caution: - Systemic anticoagulants or antiplatelet drugs, as joint puncture may cause bleeding. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) that could mask early signs of joint infection. - Disease‑modifying antirheumatic drugs (DMARDs) in patients with mixed inflammatory and degenerative joint disease. - Patients with severe renal impairment should be monitored, as hyaluronate clearance may be reduced.